Concise Review: Genetic and Epigenetic Regulation of Cardiac Differentiation from Human Pluripotent Stem Cells

Jun Fujita, Shugo Tohyama, Yoshikazu Kishino, Marina Okada, Yuika Morita

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Human pluripotent stem cells (hPSCs), including both embryonic stem cells and induced pluripotent stem cells, are the ideal cell sources for disease modeling, drug discovery, and regenerative medicine. In particular, regenerative therapy with hPSC-derived cardiomyocytes (CMs) is an unmet medical need for the treatment of severe heart failure. Cardiac differentiation protocols from hPSCs are made on the basis of cardiac development in vivo. However, current protocols have yet to yield 100% pure CMs, and their maturity is low. Cardiac development is regulated by the cardiac gene network, including transcription factors (TFs). According to our current understanding of cardiac development, cardiac TFs are sequentially expressed during cardiac commitment in hPSCs. Expression levels of each gene are strictly regulated by epigenetic modifications. DNA methylation, histone modification, and noncoding RNAs significantly influence cardiac differentiation. These complex circuits of genetic and epigenetic factors dynamically affect protein expression and metabolic changes in cardiac differentiation and maturation. Here, we review cardiac differentiation protocols and their molecular machinery, closing with a discussion of the future challenges for producing hPSC-derived CMs. Stem Cells 2019.

Original languageEnglish
JournalStem Cells
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Pluripotent Stem Cells
Epigenomics
Cardiac Myocytes
Transcription Factors
Histone Code
Induced Pluripotent Stem Cells
Untranslated RNA
Regenerative Medicine
Gene Regulatory Networks
DNA Methylation
Drug Discovery
Embryonic Stem Cells
Stem Cells
Heart Failure
Genes
Proteins

Keywords

  • Cardiac
  • Differentiation
  • Epigenetics
  • Pluripotent stem cells
  • Transcription factors

ASJC Scopus subject areas

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Cite this

Concise Review : Genetic and Epigenetic Regulation of Cardiac Differentiation from Human Pluripotent Stem Cells. / Fujita, Jun; Tohyama, Shugo; Kishino, Yoshikazu; Okada, Marina; Morita, Yuika.

In: Stem Cells, 01.01.2019.

Research output: Contribution to journalReview article

@article{2760d792fcc44d588a674fbac3c024c4,
title = "Concise Review: Genetic and Epigenetic Regulation of Cardiac Differentiation from Human Pluripotent Stem Cells",
abstract = "Human pluripotent stem cells (hPSCs), including both embryonic stem cells and induced pluripotent stem cells, are the ideal cell sources for disease modeling, drug discovery, and regenerative medicine. In particular, regenerative therapy with hPSC-derived cardiomyocytes (CMs) is an unmet medical need for the treatment of severe heart failure. Cardiac differentiation protocols from hPSCs are made on the basis of cardiac development in vivo. However, current protocols have yet to yield 100{\%} pure CMs, and their maturity is low. Cardiac development is regulated by the cardiac gene network, including transcription factors (TFs). According to our current understanding of cardiac development, cardiac TFs are sequentially expressed during cardiac commitment in hPSCs. Expression levels of each gene are strictly regulated by epigenetic modifications. DNA methylation, histone modification, and noncoding RNAs significantly influence cardiac differentiation. These complex circuits of genetic and epigenetic factors dynamically affect protein expression and metabolic changes in cardiac differentiation and maturation. Here, we review cardiac differentiation protocols and their molecular machinery, closing with a discussion of the future challenges for producing hPSC-derived CMs. Stem Cells 2019.",
keywords = "Cardiac, Differentiation, Epigenetics, Pluripotent stem cells, Transcription factors",
author = "Jun Fujita and Shugo Tohyama and Yoshikazu Kishino and Marina Okada and Yuika Morita",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/stem.3027",
language = "English",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Concise Review

T2 - Genetic and Epigenetic Regulation of Cardiac Differentiation from Human Pluripotent Stem Cells

AU - Fujita, Jun

AU - Tohyama, Shugo

AU - Kishino, Yoshikazu

AU - Okada, Marina

AU - Morita, Yuika

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Human pluripotent stem cells (hPSCs), including both embryonic stem cells and induced pluripotent stem cells, are the ideal cell sources for disease modeling, drug discovery, and regenerative medicine. In particular, regenerative therapy with hPSC-derived cardiomyocytes (CMs) is an unmet medical need for the treatment of severe heart failure. Cardiac differentiation protocols from hPSCs are made on the basis of cardiac development in vivo. However, current protocols have yet to yield 100% pure CMs, and their maturity is low. Cardiac development is regulated by the cardiac gene network, including transcription factors (TFs). According to our current understanding of cardiac development, cardiac TFs are sequentially expressed during cardiac commitment in hPSCs. Expression levels of each gene are strictly regulated by epigenetic modifications. DNA methylation, histone modification, and noncoding RNAs significantly influence cardiac differentiation. These complex circuits of genetic and epigenetic factors dynamically affect protein expression and metabolic changes in cardiac differentiation and maturation. Here, we review cardiac differentiation protocols and their molecular machinery, closing with a discussion of the future challenges for producing hPSC-derived CMs. Stem Cells 2019.

AB - Human pluripotent stem cells (hPSCs), including both embryonic stem cells and induced pluripotent stem cells, are the ideal cell sources for disease modeling, drug discovery, and regenerative medicine. In particular, regenerative therapy with hPSC-derived cardiomyocytes (CMs) is an unmet medical need for the treatment of severe heart failure. Cardiac differentiation protocols from hPSCs are made on the basis of cardiac development in vivo. However, current protocols have yet to yield 100% pure CMs, and their maturity is low. Cardiac development is regulated by the cardiac gene network, including transcription factors (TFs). According to our current understanding of cardiac development, cardiac TFs are sequentially expressed during cardiac commitment in hPSCs. Expression levels of each gene are strictly regulated by epigenetic modifications. DNA methylation, histone modification, and noncoding RNAs significantly influence cardiac differentiation. These complex circuits of genetic and epigenetic factors dynamically affect protein expression and metabolic changes in cardiac differentiation and maturation. Here, we review cardiac differentiation protocols and their molecular machinery, closing with a discussion of the future challenges for producing hPSC-derived CMs. Stem Cells 2019.

KW - Cardiac

KW - Differentiation

KW - Epigenetics

KW - Pluripotent stem cells

KW - Transcription factors

UR - http://www.scopus.com/inward/record.url?scp=85065920886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065920886&partnerID=8YFLogxK

U2 - 10.1002/stem.3027

DO - 10.1002/stem.3027

M3 - Review article

C2 - 31021504

AN - SCOPUS:85065920886

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

ER -